comparemela.com
Home
Live Updates
Datopotamab Deruxtecan Biologics License Application Accepte
Datopotamab Deruxtecan Biologics License Application Accepte
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Application based on results from the TROPION-Breast01 phase 3 trial
Additional BLA under review in the U.S. for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan for patients with...
Related Keywords
Japan ,
United States ,
Sapporo ,
Hokkaido ,
China ,
America ,
Susan Galbraith ,
Ken Takeshita ,
Daiichi Sankyo ,
European Society For Medical Oncology ,
World Health Organization ,
National Cancer Institute ,
Sapporo Medical University ,
Drug Administration ,
Merck Co Inc ,
Astrazeneca ,
Nasdaq ,
Biologics License Application ,
Prescription Drug User Fee Act ,
Presidential Symposium ,
European Society ,
Medical Oncology ,
Antonio Breast Cancer Symposium ,
Global Head ,
Executive Vice President ,
North America ,
Hormone Receptor Positive ,
Breast Cancer ,
Datopotamab Deruxtecan ,
Astrazeneca Collaboration ,
Global Cancer Observatory ,
Accessed April ,
Cancer Res ,
Markets ,